NKILA and breast carcinoma: For example, CCDC144NL-AS1 has been reported to promote the progression of CRC, hepatocellular carcinoma, and osteosarcoma (43–45); lncRNA MNX1-AS1 is an oncogenic propellant in a variety of tumors, including esophageal squamous cell carcinoma (46); NKILA can promote tumor immune escape by interacting with NF-κB in breast cancer (47); TEX41 promotes the malignant behaviors of skin cutaneous melanoma and lymphoblastic leukemia (48, 49).